Macitentan in chronic thromboembolic pulmonary hypertension (CTEPH): experience from the OPUS registry
N. Kim (La Jolla, United States of America), R. Channick (Boston, United States of America), V. Mclaughlin (Ann Arbor, United States of America), J. Mcconnell (Louisville, United States of America), D. Poch (La Jolla, United States of America), M. Brand (Allschwil, Switzerland), E. Muros-Le Rouzic (Allschwil, Switzerland), M. Selej (South San Francisco, United States of America), K. Chin (Dallas, United States of America)
Source: International Congress 2018 – Chronic thromboembolic pulmonary hypertension
Session: Chronic thromboembolic pulmonary hypertension
Session type: Oral Presentation
Number: 4945
Disease area: Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Kim (La Jolla, United States of America), R. Channick (Boston, United States of America), V. Mclaughlin (Ann Arbor, United States of America), J. Mcconnell (Louisville, United States of America), D. Poch (La Jolla, United States of America), M. Brand (Allschwil, Switzerland), E. Muros-Le Rouzic (Allschwil, Switzerland), M. Selej (South San Francisco, United States of America), K. Chin (Dallas, United States of America). Macitentan in chronic thromboembolic pulmonary hypertension (CTEPH): experience from the OPUS registry. 4945
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: